Perceptive Advisors LLC Has $4.63 Million Position in Versartis, Inc. (VSAR)

Perceptive Advisors LLC lowered its position in shares of Versartis, Inc. (NASDAQ:VSAR) by 57.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,888,160 shares of the biopharmaceutical company’s stock after selling 2,519,157 shares during the period. Perceptive Advisors LLC owned approximately 5.27% of Versartis worth $4,625,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently made changes to their positions in VSAR. Teachers Advisors LLC increased its position in shares of Versartis by 9.7% during the first quarter. Teachers Advisors LLC now owns 55,244 shares of the biopharmaceutical company’s stock valued at $1,179,000 after acquiring an additional 4,876 shares in the last quarter. Vanguard Group Inc. grew its position in Versartis by 11.3% in the 1st quarter. Vanguard Group Inc. now owns 1,002,507 shares of the biopharmaceutical company’s stock worth $21,404,000 after purchasing an additional 101,578 shares during the period. Schwab Charles Investment Management Inc. grew its position in Versartis by 5.5% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 108,782 shares of the biopharmaceutical company’s stock worth $2,323,000 after purchasing an additional 5,643 shares during the period. Bank of America Corp DE grew its position in Versartis by 46.3% in the 1st quarter. Bank of America Corp DE now owns 9,482 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 3,001 shares during the period. Finally, Credit Suisse AG grew its position in Versartis by 28.0% in the 1st quarter. Credit Suisse AG now owns 27,066 shares of the biopharmaceutical company’s stock worth $576,000 after purchasing an additional 5,917 shares during the period. 49.18% of the stock is owned by institutional investors.

Versartis, Inc. (NASDAQ:VSAR) opened at $2.25 on Monday. Versartis, Inc. has a one year low of $1.60 and a one year high of $24.00. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.52 and a current ratio of 1.52.

Versartis (NASDAQ:VSAR) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.78). During the same period last year, the firm posted ($0.92) EPS. analysts expect that Versartis, Inc. will post -4.14 earnings per share for the current year.

In other news, Director Srinivas Akkaraju bought 419,700 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were bought at an average price of $2.13 per share, for a total transaction of $893,961.00. Following the purchase, the director now owns 14,955 shares in the company, valued at $31,854.15. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of Versartis stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $3.29, for a total transaction of $7,007,700.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,132,769 shares of company stock worth $7,014,761 in the last quarter. Corporate insiders own 10.90% of the company’s stock.

A number of equities research analysts have commented on the stock. ValuEngine downgraded shares of Versartis from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Cowen reaffirmed an “outperform” rating and issued a $45.00 target price on shares of Versartis in a research report on Wednesday, August 23rd. Citigroup downgraded shares of Versartis from a “buy” rating to a “neutral” rating and cut their target price for the stock from $23.00 to $3.00 in a research report on Monday, September 25th. Zacks Investment Research raised shares of Versartis from a “sell” rating to a “hold” rating in a research report on Wednesday, August 30th. Finally, Bank of America downgraded shares of Versartis from a “buy” rating to a “neutral” rating in a research report on Monday, September 25th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $7.22.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/12/11/perceptive-advisors-llc-has-4-63-million-position-in-versartis-inc-vsar.html.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Want to see what other hedge funds are holding VSAR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Versartis, Inc. (NASDAQ:VSAR).

Institutional Ownership by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply